

Lyka Labs announces Out-Licensing Deal with US based Generics Company

Mumbai, 29th May, 2017: Lyka Labs Limited, a pharmaceutical company with business across 46 countries globally in super specialty segments of Injections and Dermatology today announced its Out-Licensing / Technology Transfer Deal with a US based Generics Company.

Lyka has entered an out-licensing / Technology Transfer deal for a basket of **12 Sterile Injectable Formulations for Manufacturing, Sales & Distribution in the United State of America**. The market size of the licensed formulations is approximately **\$ 1.4 Billion as per IMS MAT March 2017**.

Lyka will be eligible for a Royalty on End Sales.

Going forward, Lyka will continue to explore opportunities to monetize its R&D capabilities in the regulated markets through out-licensing partnerships.

About Lyka Labs Limited

Lyka Labs Limited (BSE-LYKALABS/500259: NSE-LYKALABS) is a leading pharmaceutical company with strong capabilities in Sterile Preparations and Dermatology. It has a wide portfolio of 20+ Lyophilized Products and 50+ products in Dermatology. Its products are marketed across 46 markets globally. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New Formulations and New Drug Delivery System in its focus areas of Lyophilization and Dermatology and has a portfolio of over 20 products under development

For Queries, Please Contact

Lyka Labs Limited

Yogesh Shah

Chief Financial Officer

Tel: +91 22 66112200

ybshah@lykalabs.com

Registered Office

Lyka Labs Limited

4801/B & 4802/A

G.I.D.C. Industrial Estate,

Ankleshwar – 393 002

Corporate Information

BSE Code: 500259

NSE Code: LYKALABS

Website: www.lykalabs.com

CIN: L24230GJ1976PLC008738

Piyush Hindia

Company Secretary

Tel: +91 22 66112200

companysecretary@lykalabs.com

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Lyka Labs Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances